3.26
-0.07(-2.10%)
Currency In USD
| Previous Close | 3.33 |
| Open | 3.31 |
| Day High | 3.45 |
| Day Low | 3.09 |
| 52-Week High | 10.8 |
| 52-Week Low | 2.63 |
| Volume | 19,408 |
| Average Volume | 18,282 |
| Market Cap | 19.82M |
| PE | -1.98 |
| EPS | -1.57 |
| Moving Average 50 Days | 3.58 |
| Moving Average 200 Days | 4.47 |
| Change | -0.22 |
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
GlobeNewswire Inc.
Feb 05, 2026 12:00 PM GMT
Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplantREDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWI
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
GlobeNewswire Inc.
Jan 21, 2026 12:00 PM GMT
REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it will present a poster at the upcoming 2026 Tandem
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
GlobeNewswire Inc.
Dec 08, 2025 9:30 PM GMT
REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive results from its completed Phase 2 trial evaluat